AMGN - アムジェン (Amgen Inc.) アムジェン

 AMGNのチャート


 AMGNの企業情報

symbol AMGN
会社名 Amgen In (アムジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta(ペグフィルグラスチム)、Aranesp(ダルベポエチンアルファ)・EPOGEN(エポエチンアルファ)等の赤血球産生促進剤(ESAs)、Sensipar/Mimpara(シナカルセット)、XGEVA(デノスマブ)、Prolia(デノスマブ)及びNEUPOGEN(フィルグラスチム)、並びにKYPROLIS(カルミゾミブ)、Vectibix(パニツムマブ)、Nplate(ロムリプスチム)、Repatha(エボロクマブ)、BLINCYTO(ブリナトモマブ)、IMLYGIC(タルミモジュラーラパーパープ)、Corlanor(イバブラジン)など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。   アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤「アラネスプ」、白血球減少症治療剤「ニュ―ラスタ」など。  
本社所在地 One Amgen Center Drive Thousand Oaks CA 91320-1799 USA
代表者氏名 Robert A. Bradway ロバート・A・ブラッドウェイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 805-447-1000
設立年月日 29312
市場名 NASDAQ National Market System
ipoyear 1983年
従業員数 20800人
url www.amgen.com
nasdaq_url https://www.nasdaq.com/symbol/amgn
adr_tso
EBITDA EBITDA(百万ドル) 12110
終値(lastsale) 205.72
時価総額(marketcap) 133156809623.24
時価総額 時価総額(百万ドル) 133338
売上高 売上高(百万ドル) 23188
企業価値(EV) 企業価値(EV)(百万ドル) 138440
当期純利益 当期純利益(百万ドル) 8464
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.

 AMGNのテクニカル分析


 AMGNのニュース

   Global Rituximab Biosimilars Market Report 2020: Market is Expected to Recover and Reach $2.62 Billion in 2023 at a CAGR of 13.85% - Forecast to 2030 - ResearchAndMarkets.com  2021/01/08 12:16:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Rituximab Biosimilars Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global rituximab biosimilars market. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharm
   Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing  2021/01/07 20:23:27 Benzinga
Moderna Inc (NASDAQ: MRNA ), which received the fourth regulatory nod for its investigational coronavirus vaccine with the conditional approval granted Wednesday by the European Union, is leaving no stone unturned in its commercialization efforts. What Happened: Boston, Massachusetts-based Moderna said it has hired biopharma industry veteran Corinne Le Goff as chief commercial officer effective Jan. 19. She will report to CEO Stéphane Bancel, the company said. "I am thrilled to welcome Corinne to Moderna as our chief commercial officer and to the executive committee. Corinne is joining us at an important time as … Full story available on Benzinga.com
   Patent Medicine Market With Leading Players like Pfizer, Otsuka Pharmaceutical Co., Ltd. GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc. Roche Holding AG, Amgen, AbbVie, Sanofi, Bristol-Myers Squibb Company  2021/01/07 05:53:56 OpenPR
An off-the-shelf report on Patent Medicine Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as
   Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference  2021/01/06 21:00:00 PR Newswire
THOUSAND OAKS, Calif., Jan. 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio…
   These 6 Dividend Payers Look Primed for Growth in Earnings—and Payouts  2021/01/06 11:00:00 Barron's
To find some solid income prospects for 2021, Barron’s looked for nice-yielding stocks that are expected to show good earnings growth for 2020. The results: T. Rowe Price, Best Buy, United Parcel Service, Clorox, and Amgen.
   Amgen – International Chemotherapy-Induced Neutropenia Remedy Market 2020 Latest Growth – Amgen, Sanofi, Novartis AG, Ba  2020/12/19 05:37:30 Fintech Zoom
Amgen - International Chemotherapy-Induced Neutropenia Remedy Market 2020 Latest Growth – Amgen, Sanofi, Novartis AG, Baxter Worldwide – BIZNEWS -
   Amgen – Amgen Stock Is 1% Down So Far At the moment  2020/12/18 16:40:54 Fintech Zoom
Amgen - Amgen Stock Is 1% Down So Far At the moment -
   The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data  2020/12/18 12:45:00 Benzinga
Here's a roundup of top developments in … Full story available on Benzinga.com
   The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data  2020/12/18 07:45:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 17) …
   Amgen – Purpura Remedy Market 2020: Projected Big Progress To 2027  2020/12/18 07:41:15 Fintech Zoom
Amgen - Purpura Remedy Market 2020: Projected Big Progress To 2027 -
   Amgen – International Biopharmaceuticals Market 2020 Manufacturing Evaluation – Roche, Eli Lilly, Sanofi-Aventis, Amgen,  2020/12/11 04:36:46 Fintech Zoom
Amgen - International Biopharmaceuticals Market 2020 Manufacturing Evaluation – Roche, Eli Lilly, Sanofi-Aventis, Amgen, Novo Nordisk, AbbVie, Merck, Pfizer -
   Amgen – Pemphigus vulgaris remedy market is predicted to realize market development within the forecast interval of 2020 t  2020/12/11 02:15:00 Fintech Zoom
Amgen - Pemphigus vulgaris remedy market is predicted to realize market development within the forecast interval of 2020 to 2027 | Main Gamers -
   AHF Blasts Amgen Over Drug Restrictions; Asks Biden Administration to Sanction It and Others  2020/12/10 22:49:00 Business Wire
WASHINGTON--(BUSINESS WIRE)--AHF Blasts Amgen Over Drug Restrictions; Asks Biden Administration to Sanction It and Others
   Amgen – Psoriatic Arthritis Therapy World Market Report 2020-30: COVID-19 Development and Change  2020/12/10 09:22:22 Fintech Zoom
Amgen - Psoriatic Arthritis Therapy World Market Report 2020-30: COVID-19 Development and Change -
   Monoclonal antibody therapy Market 2020 Global Major Key Players: AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol – Myers Squibb Company and others upto 2022  2020/12/09 17:16:32 OpenPR
Global Monoclonal Antibody Therapy Market The global market for monoclonal antibody therapy is growing continuously and expected to reach USD ~140 Billion by the end of 2022. Market Highlights The global monoclonal antibody therapy market has been evaluated as rapidly growing market and

 関連キーワード  (医薬品 米国株 アムジェン AMGN Amgen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)